

INDEX

ADVERTISING

low tar cigarettes, 371-372

AGE FACTORS

arterial disease prevalence, 183-184

atherosclerosis and smoking relationship, 32

atherosclerosis, aortic aneurysm, and smoking relationship, 194

cardiovascular disease mortality trends, 331

cerebrovascular disease risk, 5, 8

cessation attempts, 10-11, 370, 373

CHD mortality, 7, 113, 128, 339, 352, 354

CHD relationship, 75-76, 91, 92, 101-102, 133-134

daily cigarette consumption, 10, 367, 373

intermittent claudication prevalence, 184

prevalence of smoking, 10, 259, 365-366, 373

stroke incidence, 165-166, 171

stroke mortality trends, 341

ALCOHOL CONSUMPTION

CHD mortality relationship, 111-112

CHD relationship, 68, 91

coronary calcification relationship, 32

lipoprotein level relationship, 96

stroke risk factor, 162

sudden cardiac death relationship, 104-105

ALLERGY

tobacco allergy and cardiovascular effects, 55-56, 188-189

AMISH

mortality, 126-127

AMPUTATION

healing failure and smoking, 192

ANGINA PECTORIS

carbon monoxide exposure and exercise tolerance, 186, 223

ANGINA PECTORIS—Contd.

carboxyhemoglobin level, 223

CHD manifestation, 67, 70-71

incidence in Belfast, 84

incidence in smokers with CHD, 213

risk in female smokers, 102

smoking relationship, 70, 77, 86-87

AORTA

aneurysm diagnosis, 192

aneurysm prevalence in smokers and nonsmokers, 45

atherosclerosis and nicotine exposure, 50

atherosclerosis and smoking, 22, 34, 46-48, 56

atherosclerosis as cause, 16

atherosclerosis development, 5, 18

epidemiologic data, 194-195

mortality trends, 341

tobacco smoke effects in rats, 53

ARTERIOSCLEROSIS

(See also ATHEROSCLEROSIS)

angina pectoris relationship, 70

carbon disulfide exposure relationship, 226

cardiovascular disease causation, 5

definition, 15

mortality trends, 341

percent attributable to smoking, 65

underlying process of stroke, 340

ATHEROMA

definition, 15

small arteries of myocardium, 34

ATHEROSCLEROSIS

(See also ARTERIOSCLEROSIS)

age and smoking relationship, 194

aortic aneurysm relationship, 192

atherogenesis, 19-21

cadmium exposure relationship, 227

carbon monoxide exposure relationship, 223

cardiac arrest, 69

cardiovascular disease causation, 5

INDEX

- ATHEROSCLEROSIS—Contd.**
clinical significance, 16-17
definition, 15-16
dietary cholesterol effect, 190
epidemiologic studies, 21-48
incidence in smokers and nonsmokers, 67
literature reviews, 17
mortality and smoking, 229
natural history, 17-19
nicotine effects, 216
pathophysiologic mechanisms of tobacco smoke, 48, 50-54
plasma triglyceride correlation, 181
risk factors, 205-206
severity trends, 343-344
smoking cessation effects, 5
smoking effects, 5-6
topographic distribution, 18
- BLOOD FLOW**
nicotine and tobacco smoke effects, 189
nicotine effects, 215
smoking relationship, 187-188
- BLOOD PRESSURE**
(See also **HYPERTENSION**)
CHD risk factor, 97-98, 108, 130, 134
coronary atherosclerosis relationship, 33
intermittent claudication relationship, 184
intervention trial effects, 315, 317
intervention trial for single risk factor, 300
nicotine effects, 3, 215
race factors, 77
smoking cessation relationship, 96-97
smoking relationship, 55, 96-97, 187-188
- BODY FAT**
CHD risk factors, 132
- BODY WEIGHT**
(See also **OBESITY**)
smokers versus nonsmokers, 55
smoking effect in baboons, 190
stroke incidence relationship, 163
sudden cardiac death risk factor, 104
- CADMIUM**
physiological effects, 226-227
tobacco smoke constituent, 226
- Cancer** See **NEOPLASMS**
- CARBON DISULFIDE**
arteriosclerotic diseases, as risk factor, 226
- CARBON MONOXIDE**
atherogenic effects, 5, 51-52
blood levels in smoking baboons, 190
cardiovascular disease relationship, 220, 222-224
cardiovascular effects, 230
chemistry, 219-220
exercise tolerance relationship, 186
fibrinolysis relationship, 187
myocardial infarction risk, 229
platelet adhesiveness relationship, 189-190
steelworkers' exposure and CHD mortality, 111
toxicologic effects, 9
validation of self-reported smoking cessation, 245, 261
- CARBONYL SULFIDE**
atherosclerotic effects, 225
- Catecholamines** See **EPINEPHRINE; NOREPINEPHRINE**
- CENTRAL NERVOUS SYSTEM**
nicotine effects, 213
- CEREBROVASCULAR DISEASE**
(See also **STROKE**)
atherosclerosis of cerebral vasculature, 48
cerebral thrombosis incidence, 344
cessation of smoking relationship, 168
incidence trends, 344
morbidity and mortality, 159-160
mortality trends, 329, 340
oral contraceptives relationship, 168-171
prevention, 170
risk factors, 160-162, 168-171
smoking as risk factor, 5, 8, 162-166
subarachnoid hemorrhage, 5, 8, 167
transient ischemic attacks, 166-167
- CESSATION OF SMOKING**
(See also **EX-SMOKERS; REDUCTION OF SMOKING; SMOKING INTERVENTION TRIALS**)
attempts to quit, 10-11, 369-370, 373
blood pressure correlation, 96-97

INDEX

CESSATION OF SMOKING—Contd.

- CHD epidemiology, 243-283, 300-321
- CHD mortality rates, 8-10, 122-126, 128, 293-321
- definition in intervention trials, 246-247
- following cardiovascular events, 213, 215
- intervention trial effects, 9, 252, 257-258, 261, 264-271, 275, 278-279, 282-283
- peripheral vascular disease treatment, 5, 8, 179, 190, 192, 194
- peripheral vascular effects, 187-188
- stroke mortality risk, 168
- stroke prevention, 170
- sudden cardiac death risk, 7, 105
- validation of self-reports, 244-246, 258, 261, 265, 279-280, 305, 312

CHEROOT SMOKERS

- myocardial infarction risk, 88

CHEWING TOBACCO

- intermittent claudication relationship, 186

CHOLESTEROL

(See also **DIET; LIPIDS; LIPO-PROTEINS**)

- aortic tissue levels following smoke exposure, 219
- atherogenesis relationship, 19-20, 50-54, 216-217
- atherosclerosis and diet in rabbits, 189-191
- carbon monoxide, diet, and atherosclerosis, 223
- cardiovascular disease risk and blood levels, 205
- CHD risk, 5, 7, 89, 91-93, 96-100, 127, 129-130, 136, 344
- coronary atherosclerosis and serum levels, 53
- hypercholesterolemia prevalence, 346
- intermittent claudication and serum levels, 184
- intervention trial effects, 312-313, 315, 317
- intervention trials for single risk factor, 300
- myocardial infarction and serum levels, 165
- peripheral vascular disease relationship, 180-182, 184

CHOLESTEROL—Contd.

- smoking and blood levels, 188, 224
- smoking and serum levels, 6, 56, 182
- stroke risk predictor, 161
- sudden cardiac death and serum levels, 104

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

(See also **EMPHYSEMA**)

- mortality trends, 333, 338-340
- smoking correlation, 228

CIGAR SMOKERS

- aortic lesions, 194
- CHD mortality, 8, 122
- CHD risk, 86, 128
- coronary event risk, 76-77
- former cigarette smokers, 252
- inhalation avoidance, 212
- myocardial infarction risk, 88
- peripheral vascular disease risk, 191
- stroke mortality, 163
- thiocyanate elevation, 244

COFFEE CONSUMPTION

- blood lipid effects, 182
- CHD risk factor, 91, 97
- stroke risk factor, 162

CORONARY ARTERIES

- atherosclerosis in, 18
- atherosclerotic lesions after nicotine exposure, 50
- carbon monoxide effect on lipid metabolism in, 52
- smoking and atherosclerosis in, 22-34, 56

CORONARY HEART DISEASE

(See also **MYOCARDIAL INFARCTION**)

- age factors in smoking effect, 112-113, 116-117, 128
- atherosclerosis as underlying cause, 16
- cessation of smoking and epidemiology, 5-6, 10, 122-126, 128, 293-321
- clinical manifestations, 67-71
- death certificate ascertainment, 69-70
- incidence studies, 342-343
- intervention trial effects on incidence, 9
- low risk populations, 126-127
- low yield cigarettes, 120-122, 128

INDEX

CORONARY HEART DISEASE—Contd. DIET—Contd.

mortality trends, 329, 334, 336, 338-340, 348-352
pipe and cigar smokers, 122, 128
prevalence trends, 3
prospective cohort studies, 105-113
risk assessment, 129-136
risk factor reduction and mortality trends, 344, 346-348
risk factors, 91-93, 96-97
smoking relationship, 4-8, 65-67, 113-119, 127-128
synergism among risk factors, 97-100
treatment improvements, 348

COTININE

cigar smokers' serum, 212
nicotine metabolite, 212-213
serum levels and uptake of particulates, 228
urine concentration in smoking baboons, 190
validation of self-reported cessation, 245

CROSS-CULTURAL STUDIES

atherosclerosis topographic distribution, 18
CHD incidence and mortality, 79-91

Demographic Factors See AGE FACTORS; EDUCATIONAL ATTAINMENT; RACE FACTORS; SEX FACTORS; SOCIOECONOMIC STATUS

DIABETES MELLITUS

atherogenesis relationship, 20
cardiovascular disease risk factor, 205
CHD incidence relationship, 89
CHD risk factor, 91-92
mortality trends, 334
peripheral vascular disease relationship, 179, 183, 185, 191
prevalence, 346
stroke risk factor, 162, 165

DIET

(See also **CHOLESTEROL; SATURATED FATS**)
atherogenesis correlation, 19-20
CHD mortality relationship, 112
high cholesterol diet, nicotine, and arterial damage, 50

nutritional status and smoking role in atherosclerosis, 33
treatment of peripheral vascular disease, 179

Dose-Response Relationship See SMOKING PATTERNS

DRUG INTERACTIONS

atenolol physiologic effects in smokers, 186
diazepam reactivity in smokers, 222
methacholine effects on norepinephrine, 216
norepinephrine effects of dimethylphenylpiperazinium, 216
oxytremorine effects on norepinephrine, 216
phenacetin reactivity in smokers, 222
propranolol physiologic effects in smokers, 186

EDUCATIONAL ATTAINMENT

cessation attempt frequency relationship, 369
cigarette consumption relationship, 367

ELECTROCARDIOGRAM

abnormalities as stroke risk factor, 162-163, 165
CHD risk prediction, 134
intervention effect, 282
nitrogen dioxide exposure and cardiac function, 226

EMPHYSEMA

(See also **CHRONIC OBSTRUCTIVE PULMONARY DISEASE**)

cadmium exposure as risk factor, 226
nitrogen oxides exposure as risk factor, 226
smoking relationship, 228

ENZYMES

carbon monoxide affinity, 222-223

EPINEPHRINE

nicotine effects, 213, 215-216
plasma levels and smoking, 186

ERYTHROCYTES

(See also **HEMATOCRIT**)

counts in smokers, 55
nicotine effects in rabbits, 190

INDEX

EX-SMOKERS

(See also **CESSATION OF SMOKING**)

- aortic lesions, 47, 194
- atherosclerosis mortality, 229
- CHD incidence, 82
- CHD mortality, 5-6, 8
- death risk after myocardial infarction or angina, 105
- differences from smokers, 297
- peripheral arterial disease in women, 185
- stroke mortality, 163, 168

FAMILY

wives' participation in intervention trials, 257, 260

FETUS

(See also **MATERNAL SMOKING**)

- maternal cadmium administration effects on fetal brain in rats, 227
- maternal smoking effects, 189

FIBRINOGEN

smoking effects, 55, 187

FIBRINOLYSIS

- nicotine effects, 218
- smoking effects, 55, 187

FILTER CIGARETTES

(See also **LOW YIELD CIGARETTES**)

- carbon monoxide yields, 220
- cardiovascular disease incidence, 228
- CHD mortality effects, 8
- CHD risk, 120
- hydrogen cyanide removal, 224-225
- nicotine delivery, 210
- nitrogen oxide reduction, 225

GLUCOSE

- atherogenesis and blood levels, 218
- intermittent claudication and blood levels, 184
- intolerance and peripheral vascular disease, 182
- smoking and blood levels in baboons, 55, 190

HEART RATE

- atherogenesis correlation, 218
- nicotine effects, 3, 215-216
- smoking effects, 187

HEIGHT

- CHD risk factor, 107
- stroke risk factor, 163

HEMATOCRIT

(See also **ERYTHROCYTES**)

- nicotine effects in rabbits, 190
- smoking effects, 55, 187

HEMOGLOBIN

- carbon monoxide binding, 222
- nicotine effects in rabbits, 190
- smoking effects, 55, 186-187

HEREDITY

- cadmium-induced hypertension, 227
- CHD risk factor, 91-92, 108
- coronary disease history and platelet activation, 55
- stroke risk factor, 166

HORMONES

- estrogen and myocardial infarction, 103
- nicotine effects on antidiuretic hormone secretion, 213

HYDROGEN CYANIDE

- coronary arteries and aorta effects, 52
- serum thiocyanate as metabolite, 244
- tobacco smoke constituent, 224

HYPERTENSION

(See also **BLOOD PRESSURE**)

- atherogenesis relationship, 20
- cadmium level relationship, 226-227
- cardiovascular disease risk factor, 205
- CHD risk factor, 5, 7, 89, 91-93, 127, 344
- educational campaign effects, 348
- mortality trends, 329, 341
- peripheral vascular disease relationship, 179, 181
- prevalence trends, 346
- renal artery stenosis, hypertension, and smoking relationship, 185
- stroke risk factor, 161-163, 165-166, 170, 340
- sudden cardiac death risk factor, 104

IMMUNE SYSTEM

- alterations in smokers, 55-56
- hypersensitivity and tar exposure, 228

INFLUENZA

- mortality trends, 334

INDEX

INVOLUNTARY SMOKING

- atherosclerotic cardiovascular disease etiology, 186
- cotinine in urine of nonsmokers, 212-213

KIDNEYS

- cadmium localization, 226
- nicotine metabolism, 212
- renal artery stenosis, hypertension, and smoking interrelationship, 185

LEAD

- atherosclerosis and lead in drinking water, 227

LEGISLATION

- smoking restrictions in Finland, 279-280, 316

LEUKOCYTES

- elevation in smokers, 55-56
- nicotine effects, 190

LINOLENIC ACID

- CHD incidence and consumption, 86

LIPIDS

- (See also **CHOLESTEROL**)
- atherogenesis relationship, 19-21, 52-54, 217-218
- carbon monoxide and blood levels, 223-224
- dietary cholesterol and serum level, 190
- nicotine administration and serum level, 190
- race factors and plasma levels, 77
- smoking and serum levels, 219
- smoking serum levels in baboons, 190

LIPOPROTEINS

- atherogenic role, 21
- cadmium exposure relationship in pigeons, 227
- CHD incidence, 92
- hyperlipoproteinemia and atherogenesis, 20
- hyperlipoproteinemia and peripheral vascular disease, 180-181
- oral contraceptives and smoking effects, 104
- race factors, 77
- smoking effects, 6, 53, 54, 56, 93, 96, 188, 219
- stroke relationship, 161-163

LIVER

- cadmium accumulation, 226
- cirrhosis mortality trends, 334
- lipoprotein metabolism impairment and peripheral vascular disease, 182
- nicotine metabolism, 212
- protein synthesis and carbon monoxide exposure, 222

LOW YIELD CIGARETTES

- (See also **FILTER CIGARETTES**)
- cardiovascular disease relationship, 229-230
- CHD mortality effects, 8, 120-122, 128
- smoking pattern effects, 9, 210, 218, 230, 272
- stroke mortality relationship, 164-165

LUNG CANCER

- (See also **NEOPLASMS**)
- deaths in smoking intervention trials, 306, 309
- excess deaths attributable to smoking, 65
- mortality trends, 333, 338-339

LUNGS

- nicotine metabolism, 212

LYMPHOCYTES

- smoking effects in baboons, 190

LYSOSOMES

- nicotine effects, 219

MASS MEDIA

- in smoking intervention trials, 263-264, 270, 272, 278-279, 281-283, 316

MATERNAL SMOKING

- (See also **FETUS**)
- fetal cardiovascular effects, 189
- umbilical artery changes, 219

MENOPAUSE

- CHD risk, 7, 101-104, 127

MORMONS

- CHD mortality, 126

MORTALITY

- calculations, 333, 356
- cardiovascular disease mortality trends, 329-344
- cardiovascular disease risk factor reduction effects, 344-348
- cessation of smoking effects, 8-9, 194, 293-321

INDEX

MORTALITY—Contd.

- CHD mortality and smoking relationship, 4, 7, 65–66, 113–128, 348–353
- CHD mortality trends, 339–341
- coronary care improvement effects, 348
- prospective studies of CHD mortality, 105–113

MYOCARDIAL INFARCTION

(See also **CORONARY HEART DISEASE**)

- carbon monoxide exposure correlation, 51
- carboxyhemoglobin level relationship, 223
- cardiac arrest etiology, 69
- case-fatality trends, 344
- CHD manifestation, 67
- clinical manifestations, 67–68
- discharge rate trends, 344
- free fatty acid elevation in smokers following myocardial infarction, 219
- hyperlipoproteinemia in survivors, 181
- incidence, 342–343
- mortality trends, 339–340
- nicotine and carbon monoxide delivery relationship, 229
- oral contraceptive use as risk factor, 7, 128
- smoking as risk factor, 72–75, 77–79, 84–89, 91, 101–102, 105, 108, 121, 165
- zinc deficiency correlation, 227

MYOCARDIUM

- atherosclerosis of small arteries, 34

MYOGLOBIN

- carbon monoxide binding, 222

NEOPLASMS

(See also **LUNG CANCER**)

- cancer deaths in smoking intervention trial, 306, 310
- cancer mortality in Seventh Day Adventists, 126
- cerebral neoplasms and stroke, 166
- death rates and smoking patterns, 81
- respiratory tract cancer mortality and smoking, 81

NICOTINE

- atherosclerosis pathogenesis, 5, 48, 50–51
- blood flow effects, 189
- blood pressure and heart rate effects, 3
- cardiovascular effects, 213, 215–219, 230
- chemistry, 209–212
- fibrinolysis relationship, 187
- hematologic effects, 190
- metabolism, 212–213
- myocardial infarction risk, 229
- particulate uptake and serum levels, 228
- peripheral vascular effects, 187–188
- serum lipid effects, 190
- toxicologic effects, 9
- validation of self-reported smoking cessation, 245
- yields in U.S. cigarettes, 210

NICOTINE CHEWING GUM

- smoking intervention, 270

NITROGEN OXIDES

- coronary artery and aorta effects of nitric oxide, 52
- nitric oxide, carbon monoxide, and atherosclerotic changes, 225
- tobacco smoke constituents, 225–226

NOREPINEPHRINE

- nicotine effects, 213, 215–216
- smoking and plasma levels, 186

OBESITY

(See also **BODY WEIGHT**)

- atherosclerosis and smoking interrelationships, 31, 46
- cardiovascular disease risk factor, 205
- CHD risk factor, 91, 92
- lipoprotein level relationship, 96
- stroke risk factor, 162

OCCUPATIONS

- farm laborers, 133–134
- grade of employment and CHD mortality, 110–111
- industrial workers, 275–278, 280–282, 303, 314–315
- nurses, 102
- physicians, 65, 110, 112, 123–124, 164, 297
- steelworkers, 111

INDEX

ORAL CONTRACEPTIVES

- CHD risk factor with smoking, 101-104, 128
- myocardial infarction and smoking interrelationships, 7
- stroke risk factor with smoking, 166-171
- subarachnoid hemorrhage and smoking interrelationships, 5, 8

PERIPHERAL VASCULAR DISEASE

- animal studies, 189-190
- atherosclerosis as underlying cause, 16
- cessation of smoking effects, 190-192, 194
- clinical investigations, 186-189
- diagnosis, 179
- epidemiologic studies, 182-186
- reactivity of patients to tobacco glycoprotein, 56
- risk factors, 180-182, 194
- smoking effects, 8
- treatment, 179-180

PERSONALITY

- cardiovascular disease risk factor, 205

- CHD risk factor, 91-93

PHYSICAL ACTIVITY

- cardiovascular disease risk, 205
- CHD risk, 91-92, 132
- exercise tolerance and carbon monoxide exposure, 186
- stroke incidence, 162
- treatment of peripheral vascular disease, 179

PIPE SMOKERS

- aortic lesions, 47, 194
- CHD mortality effects, 8, 122
- CHD risk, 86, 128
- coronary event risk, 76-77
- former cigarette smokers, 252
- myocardial infarction risk, 88
- peripheral vascular disease risk, 191
- stroke mortality, 163
- thiocyanate elevation, 244

PLATELETS

- adhesiveness and carbon monoxide effects, 189-190
- atherogenesis role, 217-219
- nicotine effect in rabbits, 190
- smoking effects, 6, 55-56, 187

PLATELETS—Contd.

- smoking effects in baboons, 190
- thrombocytopenia as stroke risk factor, 166

PNEUMONIA

- mortality trends, 334

PROSTAGLANDINS

- nicotine effects and atherogenesis, 218-219

RACE FACTORS

- aortic aneurysms and atherosclerosis, 194
- atherosclerosis in aorta, 46
- atherosclerosis in coronary arteries, 22, 31
- atherosclerosis severity trends, 343-344
- cardiovascular disease mortality trends, 331
- cerebrovascular disease incidence, 170
- CHD incidence, 77-79, 132-134
- CHD mortality, 339
- hypertensive disease mortality trends, 341
- lipoprotein levels, 93
- prevalence of smoking, 364-365
- smoking patterns, 77
- stroke mortality, 159, 165, 341

RECIDIVISM

- rate following intervention trials, 261-263, 265

REDUCTION OF SMOKING

- criteria for successful intervention, 245-247
- intervention trial effects, 9, 256, 258, 262, 264, 275, 279-280, 309, 311-313, 315
- peripheral vascular disease patients, 191

REFLEXES

- nicotine effects, 213

REORGANIZED CHURCH OF JESUS CHRIST OF LATTER DAY SAINTS

- mortality rates, 126

SATURATED FATS

- (See also DIET)
- consumption trends, 348
- diet and atherogenesis, 19
- lipoprotein composition relationship, 53

INDEX

SEVENTH DAY ADVENTISTS

CHD and cancer mortality, 126

SEX FACTORS

(See also **WOMEN**)

aortic aneurysm mortality, 194

brain infarction and myocardial infarction, 159

cessation attempts, 11, 373

CHD mortality, 110-113, 339

CHD mortality and smoking cessation trends, 348-352

CHD rates, 7

cigarette consumption trends, 10, 366-367, 373

lipoprotein levels, 93

peripheral vascular disease prevalence, 184-185

smoking patterns, 7

smoking prevalence, 7, 364, 373

stroke incidence, 165, 344

stroke mortality, 164

sudden cardiac death incidence, 68

SMOKING HABIT

prevalence trends, 336, 344, 346-350, 364-366, 373

Sweden, 111

SMOKING INTERVENTION TRIALS

cessation outcome, 9, 267-271, 281-283

community-based trials, 271-282, 314-318

individual clinical investigations, 249-271, 303-313, 318, 320

methodological problems, 244-249, 264-267, 280-281, 300-302

SMOKING PATTERNS

cessation rate effects, 261

CHD incidence, 81-83, 128

CHD mortality rates, 113, 115-119, 127

coronary event risk, 75-76

daily consumption trends, 373

intervention trial effects, 9

low yield cigarettes, 9

myocardial infarction incidence, 87-88

peripheral vascular disease relationship, 185

race factors, 77

reduction of smoking effects, 262

stroke mortality rates, 163-164, 171

sudden cardiac death risk, 7, 104

trends, 352

SMOKING PATTERNS—Contd.

women, 101-102, 104

SNUFF

intermittent claudication relationship, 186

SOCIOECONOMIC STATUS

CHD mortality rates, 111-112, 339, 350-352

CHD risk factor, 91

coronary atherosclerosis and smoking interrelationships, 33

STRESS

CHD risk factor, 91

STROKE

(See also **CEREBROVASCULAR DISEASE**)

atherosclerosis as underlying cause, 16

discharge rate trends, 344

incidence study, 344

mortality trends, 334, 340-341

SUDDEN CARDIAC DEATH

clinical manifestations, 68-69

risk factors, 104-105

smoking as risk factor in women, 102

smoking pattern relationship, 7, 128

TARS, TOBACCO

smoking behavior relationship, 371-372

tobacco smoke constituent, 227-228

yields in U.S. cigarettes, 228

THIOCYANATE

blood levels in smoking baboons, 190

serum levels and lipoproteins, 182

validation of self-reported smoking cessation, 244-246, 258, 261-265, 279-280, 305, 312

TOBACCO SMOKE

atherosclerosis pathogenesis, 48, 50-56

constituents, 8-9

physical and chemical characteristics, 206-209

TRIGLYCERIDES

atherosclerosis and plasma concentration, 181

CHD development and plasma levels, 84

CHD incidence, 92

INDEX

TRIGLYCERIDES—Contd.

- elevation in peripheral vascular disease, 180
- nicotine effects, 219
- stroke risk factor, 161, 165

VITAMIN D

- arterial lesions in monkeys caused by dietary excess, 50-51

WEIGHT GAIN

- cessation of smoking correlation, 96-97, 301

WOMEN

(See also **MENOPAUSE; ORAL CONTRACEPTIVES; SEX FACTORS**)

- brain infarction and LDL cholesterol, 162
- cardiovascular disease mortality trends, 331
- CHD incidence, mortality, and smoking interrelationships, 101-104, 127-128
- subarachnoid hemorrhage risk and smoking, 5, 167, 170

ZINC

- tobacco smoke constituent, 227